Is Vertex Pharmaceuticals Stock Underperforming the Dow?

Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company that engages in developing and commercializing therapies for treating serious diseases, primarily cystic fibrosis (CF.) Valued at a market cap of nearly $120.6 billion, the company’s lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi, and Kalydeco, which are collectively approved to treat people with CF.

Companies valued at $10 billion or more are generally described as “large-cap” stocks and Vertex Pharmaceuticals fits right into that category. The biotech company is a pioneer in CF research and development and has discovered, developed, and produced the first medicines to target the underlying cause of cystic fibrosis.